Literature DB >> 21772323

Fighting neurodegeneration with rapamycin: mechanistic insights.

Jordi Bové1, Marta Martínez-Vicente, Miquel Vila.   

Abstract

A growing number of studies point to rapamycin as a pharmacological compound that is able to provide neuroprotection in several experimental models of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease and spinocerebellar ataxia type 3. In addition, rapamycin exerts strong anti-ageing effects in several species, including mammals. By inhibiting the activity of mammalian target of rapamycin (mTOR), rapamycin influences a variety of essential cellular processes, such as cell growth and proliferation, protein synthesis and autophagy. Here, we review the molecular mechanisms underlying the neuroprotective effects of rapamycin and discuss the therapeutic potential of this compound for neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21772323     DOI: 10.1038/nrn3068

Source DB:  PubMed          Journal:  Nat Rev Neurosci        ISSN: 1471-003X            Impact factor:   34.870


  178 in total

Review 1.  Autophagy gone awry in neurodegenerative diseases.

Authors:  Esther Wong; Ana Maria Cuervo
Journal:  Nat Neurosci       Date:  2010-07       Impact factor: 24.884

2.  Rapamycin treatment augments motor neuron degeneration in SOD1(G93A) mouse model of amyotrophic lateral sclerosis.

Authors:  Xiaojie Zhang; Liang Li; Sheng Chen; Dehua Yang; Yi Wang; Xin Zhang; Zheng Wang; Weidong Le
Journal:  Autophagy       Date:  2011-04-01       Impact factor: 16.016

3.  Akt regulates growth by directly phosphorylating Tsc2.

Authors:  Christopher J Potter; Laura G Pedraza; Tian Xu
Journal:  Nat Cell Biol       Date:  2002-09       Impact factor: 28.824

4.  Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein.

Authors:  Wai Haung Yu; Beatriz Dorado; Helen Yvette Figueroa; Lili Wang; Emmanuel Planel; Mark R Cookson; Lorraine N Clark; Karen E Duff
Journal:  Am J Pathol       Date:  2009-07-23       Impact factor: 4.307

5.  PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1.

Authors:  Sven Geisler; Kira M Holmström; Diana Skujat; Fabienne C Fiesel; Oliver C Rothfuss; Philipp J Kahle; Wolfdieter Springer
Journal:  Nat Cell Biol       Date:  2010-01-24       Impact factor: 28.824

6.  Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway.

Authors:  Pankaj Kapahi; Brian M Zid; Tony Harper; Daniel Koslover; Viveca Sapin; Seymour Benzer
Journal:  Curr Biol       Date:  2004-05-25       Impact factor: 10.834

7.  Structure of the human mTOR complex I and its implications for rapamycin inhibition.

Authors:  Calvin K Yip; Kazuyoshi Murata; Thomas Walz; David M Sabatini; Seong A Kang
Journal:  Mol Cell       Date:  2010-06-11       Impact factor: 17.970

8.  Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage.

Authors:  Celine Perier; Kim Tieu; Christelle Guégan; Casper Caspersen; Vernice Jackson-Lewis; Valerio Carelli; Andrea Martinuzzi; Michio Hirano; Serge Przedborski; Miquel Vila
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

9.  Lithium induces autophagy by inhibiting inositol monophosphatase.

Authors:  Sovan Sarkar; R Andres Floto; Zdenek Berger; Sara Imarisio; Axelle Cordenier; Matthieu Pasco; Lynnette J Cook; David C Rubinsztein
Journal:  J Cell Biol       Date:  2005-09-26       Impact factor: 10.539

Review 10.  Recent developments in yeast aging.

Authors:  Matt Kaeberlein; Christopher R Burtner; Brian K Kennedy
Journal:  PLoS Genet       Date:  2007-05-25       Impact factor: 5.917

View more
  212 in total

Review 1.  Protein degradation pathways in Parkinson's disease: curse or blessing.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  Acta Neuropathol       Date:  2012-06-29       Impact factor: 17.088

2.  Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration.

Authors:  Benjamin Dehay; Alfredo Ramirez; Marta Martinez-Vicente; Celine Perier; Marie-Hélène Canron; Evelyne Doudnikoff; Anne Vital; Miquel Vila; Christine Klein; Erwan Bezard
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-30       Impact factor: 11.205

3.  BAX channel activity mediates lysosomal disruption linked to Parkinson disease.

Authors:  Jordi Bové; Marta Martínez-Vicente; Benjamin Dehay; Celine Perier; Ariadna Recasens; Agnes Bombrun; Bruno Antonsson; Miquel Vila
Journal:  Autophagy       Date:  2014-03-26       Impact factor: 16.016

Review 4.  Molecular chaperones in Parkinson's disease--present and future.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  J Parkinsons Dis       Date:  2011       Impact factor: 5.568

5.  Subcellular distribution and activity of mechanistic target of rapamycin in aged retinal pigment epithelium.

Authors:  Bo Yu; Pei Xu; Zhenyang Zhao; Jiyang Cai; Paul Sternberg; Yan Chen
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-12-09       Impact factor: 4.799

6.  Dopaminergic control of autophagic-lysosomal function implicates Lmx1b in Parkinson's disease.

Authors:  Ariadna Laguna; Nicoletta Schintu; André Nobre; Alexandra Alvarsson; Nikolaos Volakakis; Jesper Kjaer Jacobsen; Marta Gómez-Galán; Elena Sopova; Eliza Joodmardi; Takashi Yoshitake; Qiaolin Deng; Jan Kehr; Johan Ericson; Per Svenningsson; Oleg Shupliakov; Thomas Perlmann
Journal:  Nat Neurosci       Date:  2015-04-27       Impact factor: 24.884

7.  Prenatal rapamycin results in early and late behavioral abnormalities in wildtype C57BL/6 mice.

Authors:  Peter T Tsai; Emily Greene-Colozzi; June Goto; Stefanie Anderl; David J Kwiatkowski; Mustafa Sahin
Journal:  Behav Genet       Date:  2012-12-12       Impact factor: 2.805

Review 8.  Lysosomal impairment in Parkinson's disease.

Authors:  Benjamin Dehay; Marta Martinez-Vicente; Guy A Caldwell; Kim A Caldwell; Zhenyue Yue; Mark R Cookson; Christine Klein; Miquel Vila; Erwan Bezard
Journal:  Mov Disord       Date:  2013-04-11       Impact factor: 10.338

9.  Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: implication for Alzheimer disease.

Authors:  Zhi Tang; Erika Bereczki; Haiyan Zhang; Shan Wang; Chunxia Li; Xinying Ji; Rui M Branca; Janne Lehtiö; Zhizhong Guan; Peter Filipcik; Shaohua Xu; Bengt Winblad; Jin-Jing Pei
Journal:  J Biol Chem       Date:  2013-04-12       Impact factor: 5.157

Review 10.  Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.

Authors:  Paul C Trippier; Kristin Jansen Labby; Dustin D Hawker; Jan J Mataka; Richard B Silverman
Journal:  J Med Chem       Date:  2013-03-27       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.